A Study to Evaluate C-CAR031 in Glypican-3 (GPC3)+ Advanced/Recurrent Hepatocellular Carcinoma (HCC)

This study is testing an experimental CAR-T cell therapy called C-CAR031 for advanced liver cancer (hepatocellular carcinoma, or HCC) in patients whose tumors express a protein called GPC3. CAR-T therapy involves re-engineering a patient's own immune cells to attack cancer cells. **You may be eligible if...** - You are between 18 and 75 years old - You have confirmed advanced liver cancer (HCC) with GPC3-positive tumors - Your cancer has progressed after at least 2 prior standard treatments - Your liver function is relatively preserved (Child-Pugh score of 6 or below) - You have at least one measurable tumor and your ECOG performance status is 0 or 1 - If you have Hepatitis B, it must be controlled with antiviral therapy **You may NOT be eligible if...** - You have previously received CAR-T therapy or any GPC3-targeted therapy - You have had a liver transplant or organ transplant - You have serious heart disease, epilepsy, recent stroke, or uncontrolled lung disease - You have HIV, active Hepatitis C, or active serious infections - You are pregnant or breastfeeding - Your tumor occupies more than 50% of your liver Talk to your doctor to see if this trial is right for you.